YTTRIGA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug YTTRIGA contains one active pharmaceutical ingredient (API):

1	Yttrium ⁹⁰Y chloride UNII 1K8M7UR6O1 - YTTRIUM Y-90
	Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr). It decays by emission of beta radiation of 2.281 MeV (99.98 %) of maximal energy to stable zirconium (90Zr). 90Y-yttrium has a half-life of 2.67 days (64.1 hours).
	Read more about Yttrium ⁹⁰Y chloride

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YTTRIGA Radiopharmaceutical precursor, solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V10X	Other therapeutic radiopharmaceuticals	V Various → V10 Therapeutic radiopharmaceuticals
Discover more medicines within V10X

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1225707
ES	Centro de información online de medicamentos de la AEMPS	05322001, 05322002
FR	Base de données publique des médicaments	61931910
IT	Agenzia del Farmaco	041068014
LT	Valstybinė vaistų kontrolės tarnyba	1029596, 1064335
PL	Rejestru Produktów Leczniczych	100313470
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W52769001